Patent application number | Description | Published |
20140261058 | APPARATUSES, SYSTEMS, AND METHODS FOR ANTICIPATING AND DELIVERING MEDICATIONS FROM A CENTRAL PHARMACY TO A PATIENT USING A TRACK BASED TRANSPORT SYSTEM - Provided herein are various apparatuses, systems, and methods for transporting medication within a healthcare facility. Examples of the invention may include a car for a track-based transport system. The car may include a payload platform configured to support a payload on a payload surface; a first tilt bracket rotatably coupled to the payload platform and rotatable relative to the payload platform about a first axis orthogonal to a plane defined by the payload surface; a first bogie pivotably coupled to the tilt bracket, where the bogie is configured to pivot about a first pivot axis that is perpendicular to the first axis and perpendicular to a direction of travel of the car; and a first electric motor coupled to the first bogie and configured to receive electric power through a bus bar disposed along a track on which the car rides. | 09-18-2014 |
20140262690 | APPARATUSES, SYSTEMS, AND METHODS FOR ANTICIPATING AND DELIVERING MEDICATIONS FROM A CENTRAL PHARMACY TO A PATIENT USING A TRACK BASED TRANSPORT SYSTEM - Provided herein are various apparatuses, systems, and methods for transporting medication within a healthcare facility. An example system for connecting sections of a track having an electrically conductive bus bar may include a first end cap including an alignment ridge, where the first end cap is received at the end of a first track section having a first bus bar, and a second end cap having an alignment channel, where the second end cap is received at the end of a second track section having a second bus bar. The alignment ridge may be configured to be received within the alignment channel when the first track section and the second track section are out of alignment, and in response to the first track section being brought into alignment with the second track section, the alignment ridge and alignment channel cooperate to draw the first and second bus bar into contact. | 09-18-2014 |
Patent application number | Description | Published |
20130085901 | INVENTORY MANAGEMENT SYSTEM - A statistical inventory management system may optimize inventory investment using historical usage and/or consumption of an inventory component by determining one or more target inventory levels (e.g., replenishment levels). Historical usage data may be summed for a plurality of at least partially non-overlapping time periods that may be each equal in duration to a supplier lead-time period for the component to create lead-time usage data. The lead-time usage data may be utilized to more accurately determine future inventory levels (e.g., target inventory levels) because the lead-time usage data may have a reduced variance compared to, for example, day-to-day usage. The inventory management system may be employable by a computing system having a display module (e.g., GUI) that allows a user to receive at least one graphical representation indicative of at least one target inventory level of at least one inventory component (e.g., by selectively interacting with the display module). | 04-04-2013 |
20140195389 | INVENTORY MANAGEMENT SYSTEM - A statistical inventory management system may optimize inventory investment using historical usage and/or consumption of an inventory component by determining one or more target inventory levels (e.g., replenishment levels). Historical usage data may be summed for a plurality of at least partially non-overlapping time periods that may be each equal in duration to a supplier lead-time period for the component to create lead-time usage data. The lead-time usage data may be utilized to more accurately determine future inventory levels (e.g., target inventory levels) because the lead-time usage data may have a reduced variance compared to, for example, day-to-day usage. The inventory management system may be employable by a computing system having a display module (e.g., GUI) that allows a user to receive at least one graphical representation indicative of at least one target inventory level of at least one inventory component (e.g., by selectively interacting with the display module). | 07-10-2014 |
Patent application number | Description | Published |
20080287372 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal. | 11-20-2008 |
20100003730 | Enzymatic Synthesis of Acetoacetate Esters and Derivatives - In one embodiment, the present invention includes a method for the synthesis of an ester derivative of acetoacetate. The method includes providing a first ester of acetoacetate and providing an alcohol. The method further includes combining the first ester of acetoacetate and the alcohol in the presence of an enzyme capable of transesterification in a non-aqueous solvent to form the ester derivative of acetoacetate. The method results in the formation of the ester derivative of acetoacetate, which, in one embodiment, is monoacetoacetin. | 01-07-2010 |
20100144875 | Compositions and Methods for Preserving Brain Function - Compositions and methods for preventing, reducing, or delaying decline in one or more of cognitive function, motor function, cerebrovascular function, or behavior in animals, particularly geriatric animals, are disclosed. The compositions and methods utilize medium chain triglycerides. | 06-10-2010 |
20100261791 | Compositions and Methods for Improving or Preserving Brain Function - The present invention is related to mammalian nutrition and effects thereof in individuals with age associated cognitive decline such as Age Associated Memory Impairment (AAMI) or a dementing illness such as Alzheimer's disease or related dementia, or Mild Cognitive Impairment, such as improving performance in, or reversal, prevention, reducing and delaying decline in, one or more of cognitive function, memory, behavior, cerebrovascular function, motor function, and/or brain physiology are seen. In particular, the present invention utilizes medium chain triglycerides, in one embodiment, administered as part of a long-term treatment regimen, to preserve or improve learning, attention, motor performance, cerebrovascular function, social behavior, and to increase activity levels, particularly in aging mammals. | 10-14-2010 |
Patent application number | Description | Published |
20100034745 | Method for Reducing Levels of Disease Associated Proteins - The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1). | 02-11-2010 |
20100041751 | Method to Reduce Oxidative Damage and Improve Mitochondrial Efficiency - Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided. | 02-18-2010 |
20110003767 | Inhibitors of Acetyl-CoA Carboxylase for Treatment of Neuronal Hypometabolism - This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others. | 01-06-2011 |
20110178032 | Monoglyceride of Acetoacetate and Derivatives for the Treatment of Neurological Disorders - This invention relates to methods of using the monoglyceride of acetoacetate and metabolic precursors for the treatment, prevention, inhibition or alleviation of neurological diseases associated with neuronal hypometabolism, such as Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, age associated memory impairment (AAMI), Traumatic Brain Injury (TBI), Huntington's disease and many others. | 07-21-2011 |
20110243885 | Use of Genomic Testing and Ketogenic Compounds for Treatment of Reduced Cognitive Function - This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer's disease. | 10-06-2011 |
20120122978 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal. | 05-17-2012 |
20120196932 | Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism - Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability. | 08-02-2012 |
20130005693 | Method for Reducing Levels of Disease Associated Proteins - The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1). | 01-03-2013 |
20130225682 | Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism II - Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability. | 08-29-2013 |
20140256808 | Use of Ketogenic Compounds for Treatment of Age-Associated Memory Impairment - This invention relates to the field of therapeutic agents for the treatment of Age-Associated Memory Impairment (AAMI). In particular, the present invention utilizes compositions comprising at least one compound capable of elevating ketone body concentrations in a mammal (e.g., ketogenic compounds), administered in an amount effective for treatment or prevention of loss of cognitive function caused by reduced neuronal metabolism in AAMI. In one embodiment, the composition includes medium chain triglycerides (MCT). In another embodiment, the compositions are administered in the presence of carbohydrate. The present invention also relates to oral dosage forms, in particular, a nutritional drink comprising at least one compound capable of elevating ketone body concentrations in a mammal. | 09-11-2014 |